Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Nov;18(5):773–778. doi: 10.1111/j.1365-2125.1984.tb02541.x

Indobufen interacts with the sulphonylurea, glipizide, but not with the beta-adrenergic receptor antagonists, propranolol and atenolol.

E Elvander-Ståhl, A Melander, E Wåhlin-Boll
PMCID: PMC1463557  PMID: 6508985

Abstract

This study assessed the possible interactions of the cyclooxygenase inhibitor indobufen with one sulphonylurea, glipizide, and with two beta-adrenoceptor antagonists, one of which is extensively metabolised already in the first passage through the liver (propranolol) while the other essentially escapes biotransformation (atenolol). Indobufen was first given as a single 200 mg dose and then for a 5 day period in a dosage of 200 mg twice daily, to six healthy volunteers. Glipizide (5 mg), propranolol (80 mg) and atenolol (100 mg) were given as single doses before and during indobufen medication. The drug concentrations were measured by selective and sensitive h.p.l.c. methods. The findings suggest that the lipophilic acid indobufen can inhibit the metabolic inactivation of another lipophilic acid, glipizide, but does not interfere with the disposal of the two basic drugs, propranolol and atenolol. The increased glipizide concentrations following indobufen were associated with an enhanced blood glucose reduction. Hence, this interaction may be clinically relevant.

Full text

PDF
773

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fuccella L. M., Corvi G., Moro E., Pogliani E., Tamassia V., Tosolini G. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Eur J Clin Pharmacol. 1979 Jun 12;15(5):323–327. doi: 10.1007/BF00558435. [DOI] [PubMed] [Google Scholar]
  2. Jackson J. E., Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs. 1981 Sep;22(3):211–245. doi: 10.2165/00003495-198122030-00003. [DOI] [PubMed] [Google Scholar]
  3. Pritchard J. F., Schneck D. W., Hayes A. H., Jr Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography. J Chromatogr. 1979 Jan 1;162(1):47–58. doi: 10.1016/s0378-4347(00)82062-9. [DOI] [PubMed] [Google Scholar]
  4. Wåhlin-Boll E., Brantmark B., Hanson A., Melander A., Nilsson C. High-pressure liquid chromatographic determination of acetylsalicylic acid, salicylic acid, diflunisal, indomethacin, indoprofen and indobufen. Eur J Clin Pharmacol. 1981;20(5):375–378. doi: 10.1007/BF00615408. [DOI] [PubMed] [Google Scholar]
  5. Wåhlin-Boll E., Melander A. High-performance liquid chromatographic determination of glipizide and some other sulfonylurea drugs in serum. J Chromatogr. 1979 Dec 1;164(4):541–546. doi: 10.1016/s0378-4347(00)81560-1. [DOI] [PubMed] [Google Scholar]
  6. Yee Y. G., Rubin P., Blaschke T. F. Atenolol determination by high-performance liquid chromatography and fluorescence detection. J Chromatogr. 1979 Apr 1;171:357–362. doi: 10.1016/s0021-9673(01)95315-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES